Rova-T一线治疗广泛期小细胞肺癌的1期研究
这项1期研究评估了靶向DLL3的抗体药物偶联物Rova-T单用或联合铂类化疗一线治疗广泛期小细胞肺癌。26例患者入组四个队列,队列3(Rova-T 0.1或0.2 mg/kg联合CE)中50%确认客观缓解,中位无进展生存5.2个月,中位总生存10.3个月。较低剂量Rova-T可能与部分特殊不良事件发生率较低相关,但联合CE未见明确疗效获益。
要点
- Rova-T联合CE在广泛期小细胞肺癌一线治疗中耐受性可,但未见明确疗效增益。
- 队列3中50%患者确认客观缓解,中位PFS 5.2个月,中位OS 10.3个月。
- 较低剂量Rova-T可能与部分特殊不良事件(如浆膜腔积液)发生率较低相关。
核心结论
- 较低剂量Rova-T可能与部分Rova-T相关特殊不良事件发生率较低相关。
- Rova-T 0.2 mg/kg联合CE可耐受,但联合CE未见明确疗效获益。
研究设计与样本
- 1期研究,评估Rova-T单用或联合铂类化疗一线治疗广泛期小细胞肺癌。
- 允许入组前接受一周期CE(后改为强制),共四个队列,26例患者接受治疗。
- 队列1:Rova-T单药0.3 mg/kg每6周×2(n=4);队列2:Rova-T诱导0.3 mg/kg每6周×2后CE每21天×4(n=5);队列3:Rova-T 0.1或0.2 mg/kg每6周×2与CE每21天×4重叠(n=14);队列4:CE每21天×4后Rova-T维持0.3 mg/kg每6周×2(n=3)。
主要发现
- 中位年龄66岁,73%患者ECOG体能状态评分为1。
- 队列3中7例(50%)确认客观缓解,中位无进展生存5.2个月,中位总生存10.3个月。
- 与队列1、2、4合并相比,队列3部分Rova-T相关特殊不良事件频率较低:胸腔积液(0 vs 33%)、心包积液(0 vs 17%)、腹水(0 vs 8%)、外周水肿(36% vs 42%)、全身性水肿(0 vs 8%)、肺炎(7% vs 25%)、低白蛋白血症(0 vs 17%)。
临床怎么用
- Rova-T联合CE一线治疗广泛期小细胞肺癌未显示明确疗效获益,不支持进一步开发该联合方案。
局限性
- 研究为1期小样本探索性研究,各队列样本量小(尤其队列1、2、4合并仅12例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, a Notch pathway ligand highly expressed on SCLC cells. Rova-T was evaluated alone or in combination with platinum-based chemotherapy (cisplatin or carboplatin combined with etoposide [CE]) in frontline treatment of extensive-stage SCLC. METHODS: One cycle of CE pre-enrollment was permitted (later mandated). The following four cohorts were enrolled: Rova-T monotherapy (0.3 mg/kg, every 6 [q6] wk × 2; cohort 1; n = 4); Rova-T induction (0.3 mg/kg, q6 wk × 2) followed by CE every 21 days (q21) × 4 (cohort 2; n = 5); Rova-T (0.1 or 0.2 mg/kg, q6 wk × 2) overlapping with CE q21 × 4 (cohort 3; n = 14); and Rova-T maintenance (0.3 mg/kg, q6 wk × 2) after CE q21 × 4 (cohort 4; n = 3). RESULTS: A total of 26 patients were dosed (cohort 3: 14; cohorts 1, 2, and 4 combined: 12). Median age was 66 years, and 73% had Eastern Cooperative Oncology Group performance status of 1. In cohort 3, seven patients (50%) had confirmed objective responses, with a median progression-free survival of 5.2 months and median overall survival of 10.3 months. Compared with cohorts 1, 2, and 4 combined, cohort 3 had lower frequency of some Rova-T-related adverse events of special interest, such as pleural effusion (0 versus 33%), pericardial effusion (0 versus 17%), ascites (0 versus 8%), peripheral edema (36% versus 42%), generalized edema (0 versus 8%), pneumonia (7% versus 25%), and hypoalbuminemia (0 versus 17%). CONCLUSIONS: Lower Rova-T doses may be associated with lower incidence of some Rova-T-related adverse events of special interest. Rova-T 0.2 mg/kg plus CE (cohort 3) was tolerable; however, there was no clear efficacy benefit of adding Rova-T to CE.
引用
- Hann CL, Burns TF, Dowlati A, et al. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. J Thorac Oncol. 2021. PMID: 34242790. doi:10.1016/j.jtho.2021.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。